세계의 근골격계 질환 치료제 시장 전망(-2030년) : 약물 유형, 질환 유형, 치료 유형, 투여 경로, 유통 채널, 최종 사용자 및 지역별 분석

According to Stratistics MRC, the Global Musculoskeletal Disorders Drugs Market is accounted for $88.6 billion in 2023 and is expected to reach $135.1 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Musculoskeletal disorder drugs are pharmaceuticals designed to treat conditions affecting the muscles, bones, joints, ligaments, and tendons. These disorders encompass a range of conditions, such as arthritis, osteoporosis, and musculoskeletal pain. The drugs aim to alleviate symptoms, manage inflammation, and modify disease progression, contributing to improved mobility and overall musculoskeletal health for individuals affected by these disorders.

According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries.

Market Dynamics:

Driver:

Rising prevalence of musculoskeletal disorders

The escalating prevalence of musculoskeletal disorders acts as a key driver in the musculoskeletal disorders drugs market. Factors such as aging populations, sedentary lifestyles, and an increase in chronic conditions contribute to a growing incidence of musculoskeletal issues like arthritis, osteoporosis, and musculoskeletal pain. This rising prevalence necessitates a corresponding surge in demand for effective pharmaceutical interventions. Consequently, pharmaceutical companies are prompted to invest in research and development, leading to the discovery and production of innovative drugs, thereby propelling the growth of the market.

Restraint:

Adverse side effects and high development costs

The occurrence of adverse effects associated with certain drugs can hinder patient compliance and acceptance. Additionally, the extensive research, development, and clinical trial processes contribute to elevated development costs. The financial burden of these costs may impede pharmaceutical companies from bringing novel and potentially groundbreaking musculoskeletal drugs to market promptly, limiting treatment options for patients impacting the overall growth and accessibility of effective therapies in the market.

Opportunity:

Surging demand for amyotrophic lateral sclerosis drugs

The increasing demand for amyotrophic lateral sclerosis drugs presents a notable opportunity in the musculoskeletal disorders drugs market. As awareness grows, there is a rising need for effective treatments to address this debilitating neurodegenerative disease. Pharmaceutical companies investing in amyotrophic lateral sclerosis drug development can tap into this expanding market, meeting the unmet medical needs of patients. Additionally, this contributes to the overall growth of the market.

Threat:

Insufficient availability of healthcare professionals

Musculoskeletal disorders often require specialized care, diagnosis, and treatment from healthcare professionals such as rheumatologists, orthopedic specialists, and physical therapists. The shortage of these professionals can result in delayed or inadequate patient care, hindering the proper identification and management of musculoskeletal disorders. This scarcity may lead to increased patient wait times, limited access to expert opinions, and challenges in implementing comprehensive treatment plans, affecting overall market growth.

COVID-19 Impact:

The COVID-19 pandemic has impacted the musculoskeletal disorder drug market in various ways. Lockdowns, disruptions in healthcare services, and economic uncertainties have influenced patient access to treatments. Delayed elective procedures and routine care appointments have affected drug consumption patterns. However, increased awareness of musculoskeletal health and the development of innovative telehealth solutions have partially mitigated these challenges during this period.

The juvenile idiopathic arthritis segment is expected to be the largest during the forecast period

The juvenile idiopathic arthritis segment is poised to dominate the musculoskeletal disorders drugs market during the forecast period due to the increasing incidence of juvenile idiopathic arthritis cases. Rising awareness, early diagnosis, and evolving treatment options contribute to the segment's growth. Pharmaceutical advancements, coupled with a focus on pediatric healthcare, drive research and development activities. Additionally, favorable regulatory support and initiatives for rare diseases further propel the prominence of the segment in the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital segment is primed for substantial growth in the musculoskeletal disorders drug market. Hospitals serve as key healthcare centers for musculoskeletal disorder diagnosis, treatment, and management. The increasing prevalence of these disorders, coupled with a rising aging population, drives the demand for specialized medical care. Additionally, combined with the expanding healthcare infrastructure, the hospital segment is poised for significant growth.

Region with largest share:

Over the forecast period, North America is expected to dominate the Musculoskeletal Disorders Drugs market due to the high prevalence of musculoskeletal disorders, an aging population, and a well-established healthcare infrastructure. Additionally, increasing awareness, advanced diagnostic capabilities, and robust research and development activities contribute to the market's growth. Moreover, the presence of major pharmaceutical companies and favorable reimbursement policies further solidify North America's position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for substantial growth in the Musculoskeletal Disorders Drugs market due to increasing aging populations, lifestyle changes, and a rising prevalence of musculoskeletal disorders. Additionally, improving healthcare infrastructure, growing awareness, and rising disposable incomes contribute to increased accessibility to advanced medications. Moreover, pharmaceutical companies are likely to expand their presence in the region, fostering significant growth in the musculoskeletal disorders drugs market.

Key players in the market:

Some of the key players in Musculoskeletal Disorders Drugs Market include Pfizer Inc., Novartis AG, Johnson & Johnson, Amgen Inc., AbbVie Inc., Roche Holding AG, Merck & Co., Inc., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd. and Gilead Sciences, Inc.

Key Developments:

In Jun 2022, Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana's microRNA targeting approach.

In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.

Drug Types Covered:

• Analgesics
• Corticosteroids
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Other Drug Types

Disorder Types Covered:

• Fibromyalgia
• Juvenile Idiopathic Arthritis
• Osteoarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylarthritis
• Other Disorder Types

Treatment Types Covered:

• Medication
• Surgery
• Therapy
• Other Treatment Types

Route of Administrations Covered:

• Oral
• Parenteral
• Other Route of Administrations

Distribution Channels Covered:

• Hospital Pharmacy
• Online Providers
• Retail Pharmacy and Drug Stores
• Other Distribution Channels

End Users Covered:

• Diagnostic Centers
• Hospitals
• Rheumatologists
• Specialty Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Musculoskeletal Disorders Drugs Market, By Drug Type

• 5.1 Introduction
• 5.2 Analgesics
• 5.3 Corticosteroids
• 5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
• 5.5 Other Drug Types

6 Global Musculoskeletal Disorders Drugs Market, By Disorder Type

• 6.1 Introduction
• 6.2 Fibromyalgia
• 6.3 Juvenile Idiopathic Arthritis
• 6.4 Osteoarthritis
• 6.5 Psoriatic Arthritis
• 6.6 Rheumatoid Arthritis
• 6.7 Spondylarthritis
• 6.8 Other Disorder Types

7 Global Musculoskeletal Disorders Drugs Market, By Treatment Type

• 7.1 Introduction
• 7.2 Medication
• 7.3 Surgery
• 7.4 Therapy
• 7.5 Other Treatment Types

8 Global Musculoskeletal Disorders Drugs Market, By Route of Administration

• 8.1 Introduction
• 8.2 Oral
• 8.3 Parenteral
• 8.4 Other Route of Administrations

9 Global Musculoskeletal Disorders Drugs Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacy
• 9.3 Online Providers
• 9.4 Retail Pharmacy and Drug Stores
• 9.5 Other Distribution Channels

10 Global Musculoskeletal Disorders Drugs Market, By End User

• 10.1 Introduction
• 10.2 Diagnostic Centers
• 10.3 Hospitals
• 10.4 Rheumatologists
• 10.5 Specialty Clinics
• 10.6 Other End Users

11 Global Musculoskeletal Disorders Drugs Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Pfizer Inc.
• 13.2 Novartis AG
• 13.3 Johnson & Johnson
• 13.4 Amgen Inc.
• 13.5 AbbVie Inc.
• 13.6 Roche Holding AG
• 13.7 Merck & Co., Inc.
• 13.8 Eli Lilly and Company
• 13.9 Sanofi
• 13.10 GlaxoSmithKline plc
• 13.11 Regeneron Pharmaceuticals, Inc.
• 13.12 Biogen Inc.
• 13.13 AstraZeneca plc
• 13.14 Bristol Myers Squibb Company
• 13.15 Takeda Pharmaceutical Company Limited
• 13.16 F. Hoffmann-La Roche Ltd.
• 13.17 Gilead Sciences, Inc.